Autolus to ax 20% of staff, offload asset as lead CAR-T nears pivotal data Nabel to leave Brigham to join ex-Sanofi CSO husband at biotech startup Newly acquired Alexion pays $100M for Rhythm's speedy review voucher Roche ups its stake in RNA with $25M Ribometrix deal Mukherjee debuts 2nd cell therapy biotech with an eye on solid tumors Pfizer taps Dewpoint Therapeutics in $239M dystrophy drug deal Bayer's VC arm leads $105M round for 'gene circuit' startup Senti Bio Hologic's M&A march continues with $230M Biotheranostics deal How engineered protein patches could boost immunotherapy Goodbye pill, hello science: Pfizer debuts redesigned logo with double helix Featured Story | By Nick Paul Taylor Autolus Therapeutics is set to reduce its headcount by around 20% and seek a partner for one of its dual-targeted CAR-T candidates. The changes will increase Autolus’ focus on CD19 CAR-T cell therapy AUTO1 ahead of the anticipated delivery of pivotal data on the candidate next year. read more |
| |
|---|
|
| Thank you to Catalent for sponsoring this year's JPM 2021 coverage. |
Top Stories By Nick Paul Taylor Betsy Nabel is stepping down as the president of Brigham and Women’s Hospital to enter biotech. Nabel is reportedly set to join her husband, the former chief scientific officer of Sanofi, at a stealthy new biotech startup. read more By Ben Adams Just a few weeks after being snapped up by AstraZeneca, rare disease specialist Alexion has nabbed a priority review voucher from Rhythm that can speed up the approval of one of its late-stage meds. read more By Amirah Al Idrus First Arrakis, now Ribometrix—Roche is doubling down on drugging RNA. Its Genentech unit is teaming up with Ribometrix to discover and develop small molecules for several RNA targets in a partnership worth $25 million upfront but that could exceed $1 billion in milestones down the line. read more By Amirah Al Idrus Nearly five years after founding CAR-T biotech Vor Biopharma, renowned writer and oncologist Siddhartha Mukherjee, M.D., is taking a crack at solid tumors. His new company, Myeloid Therapeutics, launches with more than $50 million to bring its myeloid cell-based treatments into the clinic. read more By Ben Adams Fierce 15 winner Dewpoint Therapeutics has added Pfizer to its growing list of pharma partners looking to tap the startup’s next-gen approach to a host of diseases. read more By Ben Adams Leaps by Bayer has led a chunky $105 million series B round for next-gen gene therapy player Senti Biosciences. read more By Conor Hale After cracking its wallet just one day earlier for a comparatively modest tuck-in deal, Hologic has opened it a little wider for a more expansive acquisition. read more By Angus Liu Scientists at the University of Washington and the U.K.’s Medical Research Council Laboratory of Molecular Biology have designed a new protein material they say could improve the efficacy of immunotherapies for a range of infectious diseases by influencing cell signaling. read more By Beth Snyder Bulik Pfizer’s got a new blue. Two new blues in fact, with the company’s rebrand and new logo design. Gone is the staid blue oval pill background, replaced by a two-tone blue double helix spiral. The new logo signals Pfizer’s “shift from commerce to science. We’ve unlocked the pill form to reveal the core of what we do,” Pfizer explains on its website. read more Resources Sponsored By: Polpharma Biologics Innovative cell lines and early process development are critical to generate a high producing cell lines alongside a USP strategy to meet high quality standards. Sponsored By: Blue Matter Biopharma companies in rare diseases: How to maximize the odds of success by becoming a valued member of the unique “rare disease ecosystem.” Sponsored by: Cytiva A one-stop hub for Cytiva resources to support process development and manufacturing of your novel molecule Sponsored by: GenScript A significant number of new treatments have been approved so far, but some manufacturing and regulatory guidelines pose challenges for advanced therapies, leading to poor production yields. Sponsored by: Catalent Cell and gene therapies hold the promise to offer novel therapeutic avenues for individuals facing serious medical conditions, but bringing them through the clinical trial process introduces a level of supply chain risk and complexity. Sponsored by: AllianceRx Walgreens Prime Gene and cell therapy are shifting paradigms for manufacturers, patients, healthcare providers and pharmacies. We invite you to learn more by reading Gene and Cell Therapy: A New Age of Medicine. Sponsored by: Catalent Autologous cell therapies have seen propelled growth since 2017, with the spotlight on the first FDA approval of a chimeric antigen receptor (CAR) T cell immunotherapy, Kymriah® (tisagenlecleucel), for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia. Sponsored by: Metabolon Learn six ways metabolomics provides greater confidence, higher success rates and complements the work of your in-house teams for your drug development pipeline. Sponsored by: Cytiva Human pluripotent stem cells (PSCs) have huge potential to produce cell therapies for many clinical areas. Here we describe a controlled, automated, and defined manufacturing process to fuel demand. Sponsored by: Covance Download the whitepaper to learn how your safety organization can implement automation technologies to enable process and cost efficiencies, improve resource allocation and ensure compliance and quality. Sponsored By: BBK Worldwide The BBK Worldwide Study Voices 2020 survey gives voice to the healthcare consumer in the wake of COVID-19 and reveals important insights for clinical trial enrollment and engagement. Sponsored by: Premier Research Browse the latest learnings and insights from our clinical development professionals. Sponsored by: Rousselot This infographic describes the benefits of GelMA in various biomedical applications and how X-Pure® GelMA can help you in your developments. Sponsored by: Aldevron Gene and cell therapy organizations are asked to balance the need for rapid clinical progression and stringent quality expectations throughout development. In this document, Aldevron provides an in-depth look at preparing for plasmid manufacturing based on our years of experience. Sponsored By: Outer Edge Technology A sound Cloud Strategy provides the flexibility and tools businesses need to quickly adapt and operate securely in an ever-changing remote work environment. Learn how your company can cost-effectively empower its employees to be productive and secure while working remotely. Sponsored by: Catalent Learn about drug product process development challenges and risks, the difference between innovator and biosimilar drug product process development, and more during the drug product process development phase. Sponsored by: Catalent Learn about proven strategies for a successful product launch, including cross-functional team collaboration, risk management and using the right project management tools. Sponsored by: Catalent This eBook provides insights on key approaches and considerations for preparing your drug development program for long-term success. Sponsored by: Catalent In this webinar, pharmaceutical scientists present real-life examples of challenges they’ve overcome in the transfer of oral small molecules from a dedicated early-phase development site to a dedicated late-phase manufacturing site. Sponsored by: Outer Edge Technology Cybercriminals Are Actively Exploiting The Coronavirus Pandemic To Gain Entry To Enterprise Networks. Don’t Let Your Company Become The Next Ransomware Headline -- Make These Changes Now! Sponsored by: Catalent Get insights on key considerations for a successful tech transfer process for manufacturing a biologic drug product, including a case study on overcoming challenges in a process transfer for a sterile diluent. Sponsored by: Catalent Pharmaceutical and biotech companies are spending years developing drugs or promising new biologics, all with the hopes of saving or enhancing patients’ lives. It’s a “race to the finish” in some cases, and the quicker a company can get its product to patients, the better. Sponsored by: Catalent In a BioPharma Dive industry survey, planning and forecasting were identified as top concerns for trial sponsors. In response to this need, the CSM team at Catalent has developed a methodology for identifying, evaluating, and proactively managing the inherent risks involved in clinical trial supply chain management. Sponsored by: Catalent Learn about a real-world example of how clinical supply management expertise was applied to overcome inventory challenges for a complex, global study. Sponsored by: Catalent Whether a study is simple or highly complex, forecasting and simulation reports serve as data driven communication tools to help minimize risks and keep the study on track. Learn more about forecasting solutions for informed decision making and supporting contingency planning for clinical study. Sponsored by: Catalent Learn how to drive excellence within the forecasting process and utilize forecasting throughout the clinical study to better plan clinical supply budgets and project timelines. Explore how to identify potential supply-related issues before they can negatively impact your study. Fierce JPM Week January 11–13, 2021, 10AM ET | Virtual Event Virtual Clinical Trials Summit February 9-10, 2021 | Virtual Event | 